Comparison Overview

SpringWorks Therapeutics

VS

Avantor

SpringWorks Therapeutics

100 Washington Blvd, Stamford, Connecticut, 06902, US
Last Update: 2025-03-05 (UTC)
View Profile
Between 750 and 799
http://www.springworkstx.com

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 388
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Avantor

100 Matsonford Rd, Radnor Township, Pennsylvania, undefined, US
Last Update: 2025-03-04 (UTC)
Between 750 and 799
http://avantorsciences.com

Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 12,023
Subsidiaries: 4
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/springworks-therapeutics.jpeg
SpringWorks Therapeutics
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/avantorinc.jpeg
Avantor
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
SpringWorks Therapeutics
100%
Compliance Rate
0/4 Standards Verified
Avantor
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for SpringWorks Therapeutics in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Avantor in 2025.

Incident History — SpringWorks Therapeutics (X = Date, Y = Severity)

SpringWorks Therapeutics cyber incidents detection timeline including parent company and subsidiaries

Incident History — Avantor (X = Date, Y = Severity)

Avantor cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/springworks-therapeutics.jpeg
SpringWorks Therapeutics
Incidents

No Incident

https://images.rankiteo.com/companyimages/avantorinc.jpeg
Avantor
Incidents

No Incident

FAQ

Avantor company demonstrates a stronger AI Cybersecurity Score compared to SpringWorks Therapeutics company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Avantor company has disclosed a higher number of cyber incidents compared to SpringWorks Therapeutics company.

In the current year, Avantor company and SpringWorks Therapeutics company have not reported any cyber incidents.

Neither Avantor company nor SpringWorks Therapeutics company has reported experiencing a ransomware attack publicly.

Neither Avantor company nor SpringWorks Therapeutics company has reported experiencing a data breach publicly.

Neither Avantor company nor SpringWorks Therapeutics company has reported experiencing targeted cyberattacks publicly.

Neither SpringWorks Therapeutics company nor Avantor company has reported experiencing or disclosing vulnerabilities publicly.

Neither SpringWorks Therapeutics nor Avantor holds any compliance certifications.

Neither company holds any compliance certifications.

Avantor company has more subsidiaries worldwide compared to SpringWorks Therapeutics company.

Avantor company employs more people globally than SpringWorks Therapeutics company, reflecting its scale as a Biotechnology Research.

Neither SpringWorks Therapeutics nor Avantor holds SOC 2 Type 1 certification.

Neither SpringWorks Therapeutics nor Avantor holds SOC 2 Type 2 certification.

Neither SpringWorks Therapeutics nor Avantor holds ISO 27001 certification.

Neither SpringWorks Therapeutics nor Avantor holds PCI DSS certification.

Neither SpringWorks Therapeutics nor Avantor holds HIPAA certification.

Neither SpringWorks Therapeutics nor Avantor holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References